-
-
As experienced physicians understand, heart failure can be a difficult diagnosis to establish in the emergency department setting, especially when there are factors that may complicate a patients presentation. This issue of Emergency Medicine Reports reviews the role and clinical utility of brain natriuretic peptide in the management of patients suspected of having heart failure upon presentation to the ED
-
In the Pipeline
-
Almotriptan malate (Axert) a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, otherwise known as a triptan, was approved by the U.S. Food and Drug Administration (FDA) in May 2001.
-
In other legislation favorable to pharmacists, the Senate Committee on Health, Education, Labor, and Pensions recently passed a bipartisan bill that would provide two student loan repayment programs for certain pharmacists. The bill now moves on to the Senate floor for consideration.
-
-
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA):
-
Emergency medicine physicians routinely manage patients with neurologic toxicity due to drugs and chemicals. The causes of these toxicities are diverse. The focus of this article will be on the manifestations of drugs in the CNS, along with management recommendations.
-
-
Organizations unveil patient safety road map; PA state legislature puts patient safety in spotlight